tiprankstipranks
Trending News
More News >
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
US Market

Intellia Therapeutics (NTLA) Financial Statements

Compare
4,668 Followers

Intellia Therapeutics Financial Overview

Intellia Therapeutics's market cap is currently $1.39B. The company's EPS TTM is $-0.92; its P/E ratio is -2.78; Intellia Therapeutics is scheduled to report earnings on November 6, 2025, and the estimated EPS forecast is $-0.96. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue$ 57.88M$ 36.27M$ 52.12M$ 33.05M$ 57.99M
Gross Profit$ 47.59M$ 27.30M$ 44.55M$ 26.16M$ -92.41M
Operating Income$ -534.26M$ -515.29M$ -458.16M$ -267.85M$ -136.58M
EBITDA$ -523.98M$ -506.31M$ -450.59M$ -260.96M$ -130.27M
Net Income$ -519.02M$ -481.19M$ -474.19M$ -267.89M$ -134.23M
Balance Sheet
Cash & Short-Term Investments$ 601.51M$ 912.22M$ 1.19B$ 748.69M$ 597.37M
Total Assets$ 1.19B$ 1.30B$ 1.52B$ 1.29B$ 676.32M
Total Debt$ 210.20M$ 115.35M$ 130.70M$ 74.02M$ 39.30M
Net Debt$ 21.02M$ -111.40M$ -392.80M$ -49.38M$ -120.72M
Total Liabilities$ 319.06M$ 250.81M$ 284.53M$ 254.22M$ 149.25M
Stockholders' Equity$ 871.96M$ 1.05B$ 1.24B$ 1.04B$ 527.07M
Cash Flow
Free Cash Flow$ -354.66M$ -408.07M$ -391.68M$ -237.79M$ -53.50M
Operating Cash Flow$ -348.88M$ -394.09M$ -333.29M$ -225.03M$ -49.91M
Investing Cash Flow$ 125.57M$ -31.35M$ 160.31M$ -550.78M$ -214.49M
Financing Cash Flow$ 185.75M$ 130.32M$ 582.96M$ 736.69M$ 371.78M
Currency in USD

Intellia Therapeutics Earnings and Revenue History

Intellia Therapeutics Debt to Assets

Intellia Therapeutics Cash Flow

Intellia Therapeutics Forecast EPS vs Actual EPS